Skip to content
Open access · CC-BY via OpenAlex

Clinical evidence for the use of NAD+ precursors to slow aging

Subhash Khatri, Mahmoud Abdellatif, Simon Sedej

Geromedicine · 2025 · ▲ 2 citations

Abstract

Significant progress in clinical care has extended human life expectancy to unprecedented levels. However, this trend has been parallelled by a rise in years lived with poor health, posing profound challenges not only to individual quality of life, but also to substantial medical and socioeconomic burdens at the population level. This underscores the urgent need for strategies that extend healthspan(definition) alongside lifespan. In this regard, nicotinamide adenine dinucleotide (NAD+) has emerged as a central metabolic cofactor and signaling molecule that regulates processes fundamental to health and longevity, including energy metabolism, mitochondrial function, inflammation, and DNA repair. Importantly, intracellular NAD+ levels decline with age across multiple tissues and organ systems, and restoring NAD+ content has been shown to reinstate cellular and physiological function in various model systems. Among the strategies to augment NAD+, supplementation with its precursors, namely nicotinic acid/niacin, nicotinamide, nicotinamide riboside, and nicotinamide mononucleotide, represents the most practical and extensively studied approach. Over the past two decades, preclinical research and an increasing number of clinical trials have investigated the therapeutic potential of these precursors in preventing or reversing age-associated decline and pathologies. In this review, we synthesize recent clinical advances, critically evaluate the promise and limitations of NAD+ precursor supplementation, and discuss future directions for leveraging NAD+ metabolism to improve healthspan in a rapidly aging global population.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.70401/geromedicine.2025.0008
Canonical
link ↗
Fetched
2026-10-09 MST

Cite this

APA
Khatri, S., Abdellatif, M., &amp; Sedej, S. (2025). Clinical evidence for the use of NAD+ precursors to slow aging. <em>Geromedicine</em>. https://doi.org/10.70401/geromedicine.2025.0008
Vancouver
Khatri S, Abdellatif M, Sedej S. Clinical evidence for the use of NAD+ precursors to slow aging. Geromedicine. 2025. doi:10.70401/geromedicine.2025.0008.
BibTeX
@article{subhash2025Clinic, title = {Clinical evidence for the use of NAD+ precursors to slow aging}, author = {Subhash Khatri and Mahmoud Abdellatif and Simon Sedej}, journal = {Geromedicine}, year = {2025}, doi = {10.70401/geromedicine.2025.0008}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings